Switch to:

Ratios

vs
industry
vs
history
P/E(ttm) 21.59
FVD's P/E(ttm) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 21.59 )
Ranked among companies with meaningful P/E(ttm) only.
FVD' s P/E(ttm) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.86
Current: 21.59
0
21.86
PE(NRI) 21.59
FVD's PE(NRI) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 21.59 )
Ranked among companies with meaningful PE(NRI) only.
FVD' s PE(NRI) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 21.86
Current: 21.59
0
21.86
P/B 2.75
FVD's P/B is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 2.75 )
Ranked among companies with meaningful P/B only.
FVD' s P/B Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.76
Current: 2.75
0
2.76

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.97
FVD's Dividend Yield is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 1.97 )
Ranked among companies with meaningful Dividend Yield only.
FVD' s Dividend Yield Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.16
Current: 1.97
0
2.16
Yield on cost (5-Year) 1.97
FVD's Yield on cost (5-Year) is ranked lower than
100% of the Companies
in the Global industry.

( Industry Median: vs. FVD: 1.97 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
FVD' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 2.16
Current: 1.97
0
2.16

More Statistics

Short Percentage of Float0.00%
52-Week Range $24.15 - 29.11
Shares Outstanding (Mil)99,999,999.99
» More Articles for FVD

Headlines

Articles On GuruFocus.com
Gilead Sciences Raises Dividend by Double Digits Feb 22 2017 
Fairholme's Bruce Berkowitz Responds to Court Ruling Against Hedge Fund Suits of Fannie Mae Feb 22 2017 
Will Procter & Gamble Raise Dividend in 2017? Feb 22 2017 
The Coffee Can Portfolio Feb 22 2017 
Gernstein Fisher: What’s a $20 Trillion Debt Among Friends? Feb 22 2017 
Abbott Laboratories Declares Quarterly Dividend Feb 22 2017 
Longleaf Partners Small-Cap Fund Comments on OCI Feb 22 2017 
Longleaf Partners Small-Cap Fund Comments on Level 3 Communications Feb 22 2017 
Longleaf Partners Small-Cap Fund Comments on Scripps Networks Feb 22 2017 
Longleaf Partners Small-Cap Fund Comments on Wynn Resorts Feb 22 2017 

More From Other Websites
A Dividend ETF On The Rise Feb 22 2017
These Prescription Products Matter to Sanofi’s Growth Feb 20 2017
Novartis’s Valuation after the 4Q16 Results Feb 03 2017
Inside Novartis’s Generics Performance in 4Q16 Feb 02 2017
Analysts Expect Negative Growth for Novartis in 4Q16 Jan 23 2017
How Did Novartis’s Innovative Medicines Segment Perform? Jan 17 2017
AstraZeneca’s Lynparza Is Still a Leading PARP Inhibitor in 2016 Jan 02 2017
First Trust Advisors L.P. Announces Distributions for Exchange-Traded Funds Dec 20 2016
Teva’s Research Pipeline to Culminate in Many New Drug Launches? Nov 24 2016
The Latest on Fasinumab, a Teva-Regeneron Collaborative Drug Nov 22 2016
Teva Pharmaceutical Expects Mid-Single-Digit Growth for Generics Nov 21 2016
Performance of Novartis’s Innovative Medicines Segment in 3Q16 Nov 17 2016
Changes in Novartis’s Valuation for 3Q16 Nov 16 2016
Bernstein: Excess Risk Aversion Has Made Investors ‘Wallflowers’ Nov 16 2016
Inside AstraZeneca’s Oncology Segment Growth in 3Q15 Nov 15 2016
Inside AstraZeneca’s Revenue Fall in 3Q16 Nov 11 2016
Richard Bernstein: Don’t Fear the Bear Market Oct 24 2016
Volume Growth and Product Mix to Drive NVO’s Insulin Sales Oct 03 2016
Can Novo Nordisk Continue to Maintain Market Share in Modern Insulin? Oct 03 2016
Diabetes Care Market Expected to Offer Strong Growth for Novo Nordisk Sep 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK